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Introduction 
Autism spectrum disorder (ASD) is a group of heterogeneous childhood onset conditions 
characterized by social communication deficits, restricted interests and repetitive behaviors1.  
The estimated worldwide prevalence ranges from 6 to 14 per 1,000 in children with a 4 to 5 fold 
higher rate in boys than girls2. Because ASD has an early onset and chronic course, many 
affected individuals require lifelong care3. The core features of ASD can cause substantial 
impairments that may be amplified by behavioral and emotional problems4, 5. These co-
occurring problems are common complaints from parents of children with ASD and the focus of 
psychotropic medication and behavioral intervention in this population6, 7.  
 Concomitant psychiatric disorders are common in children with ASD 8, 9, 10. In a sample 
of 109 children with autism spectrum disorders, Leyfer et al. (2006)11 reported that 72% of the 
children (average age = 9 years; 68% IQ > 70) had at least one Diagnostic and Statistical 
Manual of Mental Disorders Fourth Edition (DSM-IV) Axis I disorder. The median number of co-
occurring psychiatric disorders was three. Children in this study were consecutive cases 
recruited from longitudinal and neuroimaging studies, unselected for psychiatric problems. 
Using an epidemiological sample of 10 to 14-year olds with DSM-IV ASD (N=112), Simonoff et 
al. (2008) 10 reported a 3-month prevalence of 70% for concomitant psychiatric disorders with 
41% having had two or more diagnoses. The most common were Social Anxiety Disorder 
(29%), ODD (30%), and ADHD (28%). Brookman-Frazee et al. (2017)12 reported that 92% of 
children with ASD (N = 201; mean age 9 years, range 4-14) receiving publicly funded mental 
health services in Southern California met criteria for another psychiatric disorder. The most 
frequently reported psychiatric disorders were ADHD (78%), ODD (58%), and Anxiety disorders 
(56%). 
In contrast, a randomly selected community sample of 986 children and adolescents with 
intellectual disability from a Dutch province reported much lower 1-year prevalence rates, with 
only 41% of those screening positive for an ASD meeting criteria for any impairing DSM-IV 
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diagnosis13. Therefore, although psychiatric disorders appear common in youth with ASD, the 
range and types of disorders common to this population merits further study.  There is also a 
need to understand the demographic and clinical characteristics that are associated with these 
concomitant disorders.  
The high likelihood of a second psychiatric disorder in children with one disorder is well 
established14. This observation raises questions about uncertainty of the boundaries between 
psychiatric diagnoses in children. The overlap and shared symptomatology across diagnostic 
categories is not unique to children and has led to growing interest in transdiagnostic 
constructs15, 16, 17. 
In this report, we explore rates, patterns, and correlates of concomitant psychiatric 
disorders in a large sample of well-characterized, treatment-seeking children with ASD who 
participated in one of six federally-funded, multisite RCTs. The children in all six studies were 
recruited for disruptive behavior such as tantrums, aggression, self-injury, impulsive behavior or 
hyperactivity. We expected to find (a) high rates of concomitant psychiatric disorders, (b) higher 
rates of anxiety disorders in children with an IQ > 70, and (c) poorer response to the study 
intervention in children with more concomitant psychiatric disorders.  
 
Methods 
Participants 
The sample of 658 children (585 males and 97 females, aged 3-17 years) with ASD were 
participants in one of six multisite RCT18, 19, 20, 21, 22, 23. Table 1 shows key characteristics of the 
six studies, including treatment targets, entry criteria, and key outcome measures. All studies 
were approved by each site’s institutional review board and written informed consent was 
obtained from parents or legal guardian prior to data collection. Participants were recruited from 
a number of sources across sites and studies, including schools, the internet, the radio, 
outpatient clinics, and word of mouth. 
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Procedure 
An experienced multidisciplinary team conducted a pretreatment evaluation that included 
medical and developmental histories, as well as behavioral and diagnostic assessments. The 
diagnosis of ASD was based on the current version of the DSM at the time of the study24, 25. In 
addition to clinical assessment, ASD diagnoses were supported by either the Autism Diagnostic 
Interview-Revised26 or the Autism Diagnostic Observation Schedule27. The pretreatment 
assessment also included parent and clinician ratings (described below). Participants had to be 
healthy, meet study-specific symptom severity thresholds, and have a minimum mental age 
(e.g., receptive language > 18 months).  All drug studies required participants to be medication-
free at baseline (with the exception of stable anticonvulsant treatment for seizure disorder). The 
parent training study19 permitted children to be on psychotropic medication if stable with no 
planned changes for the duration of the six-month study. 
Measures   
Early Childhood Inventory (ECI)/ Child and Adolescent Symptom Inventory (CASI) 
The pretreatment assessment also included the ECI or CASI to screen for concomitant 
psychiatric conditions. These DSM-IV-referenced, parent-rated scales are designed to screen 
for child psychiatric disorders28, 29, 30, 31. The ECI and CASI are identical except for minor 
differences based on age. Here we used the subscales for ADHD (18 items), ODD (8 items), 
CD (10 items for ECI and 15 items for CASI), major depressive disorder and dysthymia (11 
items for ECI and 13 items for CASI), and ASD (12 items). The subscales for anxiety disorders 
(21 items for ECI and 20 items for CASI) included social phobia, generalized anxiety, and 
separation anxiety. We did not include specific phobia as it only includes one item. Previous 
studies have supported the validity of ECI and CASI subscales in children with ASD32, 33. Items 
are rated 0 (never) to 3 (very often) and can be scored in two different ways: symptom severity 
(total of scores within diagnostic category) or symptom count (number of items rated 2 or 3 
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within category). In the current study, symptom counts that met or exceeded DSM-IV criteria 
were used to define a positive screen for each diagnostic category. 
 
 
Aberrant Behavior Checklist (ABC) 
The ABC is a 58-item parent rating comprised of five subscales: Irritability (tantrums, 
aggression, and self-injurious behaviors, 15 items); Social Withdrawal (response to others, 
initiation of interaction, 16 items); Stereotypy (mannerisms and repetitive movements, 7 items); 
Hyperactivity and noncompliance (16 items); and Inappropriate Speech (repetitive vocalizations, 
4 items)34. Each item is rated 0 to 3 with higher scores indicating greater severity. Kaat et al. 
(2014)35 provided evidence of validity and normative data for children with ASD.  
Clinical Global Impression-Scale  
The Clinical Global Impression – Severity (CGI-S) subscale is a 7-point scale ranging from 1 
(normal) to 7 (among the most extremely ill patients)36.  By convention, a score of 3 (Mild) was 
used to describe a child who met criteria for ASD without associated behavioral problems. A 
score of 4 (Moderate) was required for entry in all trials. Although the pre-treatment CGI-S score 
was weighted by the specific treatment target (e.g., irritability, hyperactivity), the evaluating 
clinician incorporated all available information to assign the score. 
The Clinical Global Impression-Improvement (CGI-I) subscale is also a 7-point scale designed 
to measure overall change from baseline. Scores on the CGI-I range from 1 (Very Much 
Improved) through 4 (Unchanged) to 7 (Very Much Worse). In all six trials, scores of Much 
Improved or Very Much Improved defined positive treatment response. The CGI-I was rated by 
an independent evaluator, who was blind to treatment assignment. In this report, we used the 
CGI-I to classify treatment response at the end of the acute phase. The Handen et al. (2015)20 
study used separate CGIs for Hyperactivity/Inattention and Noncompliance, as this was a study 
for youth selected for ADHD. We used the CGI Hyperactivity/Inattention in this report. 
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Measures of Intellectual functioning 
Different tests were used across the studies to measure intellectual functioning. They included 
the Stanford-Binet Intelligence Scales: Fifth edition37; Leiter International Performance Scale-
Revised38, Mullen Scales of Early Learning39, and Slosson Intelligence Test40. Because several 
different tests were used, children were classified as > 70 or < 70 IQ. 
Statistical Methods 
Each of the six data sets was examined for missing data across common measures. Minor 
differences in the documentation of demographic data (e.g., school placement) were resolved 
by consensus (LL, CMcC) and by collapsing across levels to allow for aggregating data across 
studies. Descriptive statistics were calculated for all variables of interest and included means 
and standard deviations for continuous measures or counts and percentages for categorical 
data. The association of concomitant diagnoses was examined using generalized estimating 
equations (GEE) with a binomial distribution and a logit link41. The GEE approach was used to 
account for the correlation between participants nested within a study. Resulting association 
between diagnoses are presented as adjusted odds ratios with corresponding 95% confidence 
intervals. 
The frequency of concomitant psychiatric disorders was compared across demographic 
and clinical subgroups using Chi-square tests. In analyses with the CGI-I, only children 
receiving the active treatment were included (n = 478). When a demographic or clinical variable 
was ordinal (e.g., CGI-Severity: Moderate, Marked, Severe), associations with diagnosis were 
tested using the Cochran Armitage test for trend. For continuous variables, such as ASD 
severity score and age, subjects were stratified by the median value of the sample (e.g., age ≤ 6 
years vs > 6 years). 
 Uniform criteria were used to collapse ECI/CASI subscales for analyses. For example, 
the presence of any anxiety disorder was based on a positive screen for generalized anxiety, 
separation anxiety, or social anxiety. Similarly, the presence of any mood disorder was based 
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on a positive screen for major depressive disorder or dysthymia. The presence of any mood or 
anxiety disorder was classified as internalizing disorders; and externalizing disorders comprised   
ADHD, ODD, or CD.  
Statistical analyses were performed using SAS v. 9.4. Given the sample size and 
number of comparisons, statistical significance was assessed at the 0.01 level to control for 
false discovery rate. 
Results 
Demographics 
Table 2 shows demographic and clinical characteristics of children with ASD and their 
caregivers. In all, 73.1% of children were non-Hispanic White and 59.4% had an IQ > 70. 
Altogether, 83.5% of mothers had attended some college/trade school.  
 
Rates and patterns of concomitant disorders  
Table 3 shows positive screen rates for all diagnostic categories. With a few exceptions, rates 
were quite consistent across studies. 81.2% of the total sample met criteria for any type of 
ADHD, with most children meeting criteria for the combined subtype (49.1%). Rates for ODD 
and any anxiety disorder were 45.5% and 41.9%, respectively. CD and any mood disorders 
occurred at 11.7% and 7.5%, respectively.  As shown in Figure 1, 66.1% of the sample had two 
or more concomitant psychiatric disorders. Figure 2 depicts the diagnostic overlap in a 
proportional Venn Diagram for the three most frequently endorsed diagnostic categories of 
ADHD, ODD, and any anxiety disorder. Among children who met criteria for ADHD only 28.1% 
did not meet criteria for ODD or an anxiety disorder. In the full sample, 24% met criteria for all 
three diagnostic categories. 
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Table 4a presents associations between ADHD and other diagnostic conditions. It shows 
significant associations with most categories. All adjusted odds ratios were above 2.0, with the 
exception of mood disorders. The odds ratios indicated that the odds of children with ADHD also 
having ODD were 2.7 times higher than children without ADHD. Similarily, the odds of having an 
internalizing disorder were 2.5 times higher in children with ADHD compared to those without 
ADHD. The odds of having CD were 3 times higher in children with ADHD compared to children 
without ADHD; however the p value = .025 and the confidence interval was quite large. 
Table 4b presents associations between anxiety disorders and other diagnostic 
conditions. All values are statistically significant (p < .003) with adjusted odds ratios > 2.0. Odds 
of screening positive for an externalizing disorder were 4.2 times higher in children with an 
anxiety disorder compared to children without an anxiety disorder. 
Demographic and Clinical Characteristics of Participants with and without Concomitant 
Conditions   
Tables 5a and 5b show demographic and clinical characteristics of children with ASD 
and at least one additional psychiatric disorder (note: groups are not mutually exclusive). Table 
5a reveals no association between the presence of a concomitant disorder and sex. Children 
under the age of six years had higher rates of ODD (51.9% vs 41.1%, p = 0.007), but other 
significant associations with age were not observed.  With the exception of CD and ADHD, 
children with a concomitant disorder and those with two or more disorders were significantly 
more common in children with IQ > 70. 
Table 5b shows no association at the p <.01 level between diagnostic subtypes and 
CGI-S. Only one significant association emerged with CGI-I. Children who responded to study 
interventions were less likely to screen positive for ODD (37.6% positive responder vs 51.2% 
non responder, p = 0.003). Finally, children with more elevated ASD scores had higher rates of 
psychiatric problems in all categories, but only ADHD and externalizing disorders reached 
statistical significance at the p < 0.01 level. 
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Discussion 
This is one of the largest studies of concomitant psychiatric disorders in children with ASD 
published to date. A unique aspect of the report is the well-characterized sample, with 
longitudinal data on treatment outcome. The findings suggest that boundaries of co-occurring 
DSM-defined disorders are blurry in this sample of children with ASD seeking treatment for 
disruptive behavior. The high frequency of multiple DSM-defined disorders has been reported in 
several studies of children with ASD using different methodologies12, 8, 9, 10 
The rates and patterns of probable concomitant psychiatric disorders observed in this 
sample were similar to those reported in children with ASD receiving publicly-funded mental 
health services12. The high rates of ODD and CD in children with ADHD have been observed in 
the general pediatric population and in children with ASD14, 10. In the current sample of children 
with ASD, there was also a high co-occurrence of ADHD and anxiety disorders. Almost half (244 
of 534) of children with ADHD also screened positive for an anxiety disorder. The prevalence 
estimates for all anxiety disorders are likely understated because specific phobia was not 
included. The high co-occurrence of ADHD and anxiety disorders in youth with ASD was also 
observed by Brookman-Frazee et al. (2017)12. In the general pediatric population, by contrast, 
the review by Angold et al. (1999)14 reported significantly lower co-occurrence of ADHD and 
anxiety disorders compared to the association between ADHD and ODD/CD. In their sample of 
579 children with ADHD, the Multimodal Treatment Study of ADHD (MTA) observed a 34% rate 
of anxiety disorders (excluding specific phobia)42. This higher co-occurrence of ADHD and 
anxiety disorders in our sample of children with ASD compared to the general pediatric 
population may reflect the difficulties parents have in distinguishing between anxiety symptoms 
from ADHD symptoms such as restlessness, distractibility and disruptive behavior43. It may also 
speak to the shared etiology between disorders44, 45 . 
In the current sample, the rates of concomitant psychiatric disorders were higher in 
children with IQ > 70 than children < IQ 70. This trend was not observed in studies by Simonoff 
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et al. (2008)10 or Brookman-Frazee et al. (2017)12. The difference across IQ groups in our 
sample is greatest in anxiety disorders. This is consistent with findings in a prior study in which 
CASI anxiety scores were significantly lower in children with IQ < 70, presumably because the 
presence of language is a precondition for endorsing several anxiety items46.  
The presence of another psychiatric disorder did not drive the CGI-S ratings. For 
example, the rates of ADHD and anxiety disorders were similar across CGI-S ratings of 
Moderate, Marked or Severe. On the CGI-I, children with concomitant ODD were more likely to 
show a positive response. We note that these trials selected children with disruptive behavior 
and ADHD. That higher levels of noncompliant and defiant behavior at baseline, the essence of 
ODD, predicted higher positive response rates is not surprising given that the study treatments 
were directed at these behaviors and selection criteria would have guaranteed substantial room 
for participants to show improvements. The rate of positive response was not influenced by any 
other diagnostic category. The minor difference in the rate of positive response for children with 
or without a mood disorder fell below our predetermined significance level. Even the presence 
of two or more concomitant disorders did not reduce the rate of positive response. In the MTA 
study, Jensen et al. (2001)47 reported that the presence of multiple concomitant psychiatric 
disorders did affect outcome. Children with ADHD and multiple comorbid psychiatric disorders 
required combined mediation and behavioral intervention to respond optimally. 
The results of this study raise fundamental questions about the meaning of concomitant 
psychiatric disorders in children with ASD. The introduction of DSM-III was an important 
milestone for criteria-driven categorical diagnosis. It has also sparked extensive debate whether 
the co-occuring conditions are separate or somehow etiologically related. In a condition such as 
ASD involving many aspects of everyday life, it may not be surprising that youth with ASD would 
exhibit behaviors that fall under various diagnostic categories. Whether the patterns of co-
occuring psychiatric disorders in children with ASD observed in this study are distinct conditions 
or variable phenotypic manifestations of ASD  cannot be resolved here. The aim of this study 
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was to describe the patterns of concomitant disorders in children with ASD and to evaluate 
similarities and differences of identified subgroups. Further work on identifying subgroups of 
children with ASD using categorical diagnoses, dimensions of symptom severity or biological 
markers could lead to refinements in the psychopharmacological and behavioral interventions in 
ASD.  
 Our findings should be interpreted in light of several limitations. The children described 
in this report were participants in RCTs focused on either hyperactivity or disruptive behavior 
such as  tantrums, aggression and self-injury. The findings may not apply to all children with 
ASD. Indeed, RCTs are often criticized for neglecting external validity in favor of internal 
validity48. The concern is that over emphasis on internal validity leads to narrow entry criteria 
and limited generalizability. Despite the imposition of relatively strict entry criteria, however, the 
participants in these multisite studies appear to resemble the complex cases seen in clinic. In 
addition, study participants were enrolled from 11 cities in the US, which also supports the 
generalizability of the results. When this limitation on generalizability is appreciated, such a 
clinical sample can be very informative if the target group we wish to generalize to is similar. 
Another limitation is the high reliance on parents as informants. Parental biases in reporting may 
have contributed to the blurring of boundaries between disorders and enhanced the 
identification of concomitant disorders. There might also be misinterpretation by raters of core 
features of ASD as psychiatric symptoms. Relatedly, diagnoses were based solely on caregiver-
completed CASI/ECI symptom count cutoff scores, which do not include consideration of 
impairment, differential diagnosis, or multiple sources of information. Therefore, rates may differ 
to estimates of "caseness" based on alternative evaluative strategies. Finally, our analysis 
focused on DSM categories. We did not delve into transdiagnostic approaches or research 
domain criteria, both of which warrant further research in children with ASD. Of course, clinical 
and research realities necessitate both categorical and dimensional approaches. Categories 
have dimensions, and dimensions become categories when cutoffs are used. 
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Conclusions and clinical implications 
These data on treatment-seeking children with ASD show that psychiatric problems often occur 
in multiples. It is further evidence of heterogeneity of clinical presentation in ASD and the need 
to individualize treatment based on specific pattern of clinical manifestations. Diagnostic 
assessments of children with suspected ASD also need to be broad-based and include careful 
screening for internalizing disorders given their substantial presence in ASD. As treatments for 
the core deficits of ASD are examined, their effects on co-morbid symptomatology should also 
be carefully assessed. Lastly, comprehensive early intervention programs should be aware of 
the importance of future psychiatric comorbidity, and consider preventative interventions 
attempting to reduce the emergence of later psychopathology. 
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Table 1. Key Characteristics of the Six Multisite RCT 
Abbreviations: GUAN=Guanfacine; MPH=Methylphenidate; RIS=Risperidone; PEP=Parent education; PT=Parent Training;  
ASB= Abbreviated Stanford-Binet Intelligence Scales, fifth edition (Roid, 2003); Leiter= Leiter International Performance Scale (Roid and Miller, 
1997); MSEL= Mullen Scale of Early Learning (Mullen, 1995); NR=Not reported; SIT= Slosson Intelligence Test (Slosson, 1983); ABC-I= Aberrant 
Behavior Checklist-Irritability subscale; HSQ=Home Situation Questionnaire; CGI-I=Clinical Global Impression-Improvement; HSQ-ASD= Home 
situation Questionnaire-Autism Spectrum Disorder; CYBOCS-PDD= Children’s Yale-Brown Obsessive-Compulsive Scale-Modified for Pervasive 
Developmental Disorders; RBS-R=Repetitive Behavior Scale–Revised; ABC-H= Aberrant Behavior Checklist-hyperactivity subscale; SNAP-IV 
ADHD= Swanson, Nolan, and Pelham– version IV ADHD subscale; SNAP-IV H/I= Swanson, Nolan, and Pelham– version IV 
Hyperactivity/Impulsivity subscale; M = mean 
Study Aim    N Age 
Range 
IQ evaluation Treatment Target Outcome 
Measures 
Entry Criteria Primary finding 
Aman et al., 
2009
18
 
RIS alone 
vs. RIS + 
PT 
   124 4-14 ASB 
Leiter 
MSEL 
Irritability ABC–I 
HSQ 
CGI-I 
ABC-I > 18  
CGI-S > 4 
RIS + PT > RIS 
Bearss et al., 
2015
19
 
PT vs 
PEP 
   180 3-6 MSEL Irritability ABC-I 
HSQ-ASD 
CGI-I 
ABC-I > 15  
CGI-S > 4 
PT > PEP 
Handen et al., 
2015
20
 
 
ATX vs 
placebo 
and PT vs 
no PT 
   128 5-14 ASB 
MSEL 
Hyperactivity and 
Inattention 
CGI-I 
SNAP 
HSQ 
ABC 
 
SNAP-IV M > 1.5  
CGI-S > 4 
ATX & PT > placebo 
RUPP Autism 
Network, 2002
21
  
RIS vs. 
Placebo 
   101 5-17 NR Irritability ABC-I 
CGI-I 
ABC-I > 18  
CGI-S > 4 
RIS > Placebo 
RUPP Autism 
Network, 2005
22
  
MPH vs. 
Placebo 
   72 5-17 SIT Hyperactivity ABC-H 
CGI-I 
SNAP-IV ADHD > 
27 
SNAP-IV H-I > 10 
CGI-S > 4 
MPH > Placebo 
Scahill et al., 
2015
23
 
GUAN vs 
Placebo 
   62 5-14 ASB 
MSEL 
Hyperactivity ABC-H 
ADHD Rating Scale 
CGI-I 
ABC-H > 24 
 CGI-S > 4 
GUAN > Placebo 
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Table 2. Demographic and Clinical Characteristics of Children with ASD 
 
Characteristics 
N (%), unless otherwise noted 
N = 658 
Age (years), Mean ± SD 7.2 ± 2.6 
Race  
Non-Hispanic White 481 (73.1%) 
Non-Hispanic Black 65 (9.9%) 
Asian 29 (4.4%) 
Hispanic/Latino 54 (8.2%) 
Other 29 (4.4%) 
Maternal Education (n = 557)a  
High School Graduate or Less 91 (16.3%) 
Some College/Trade school or 4 year degree 385 (69.1%) 
Graduate or Professional school 80 (14.4%) 
Not in household 1 (0.2%) 
Intelligence Quotient (n = 633)b  
< 70 257 (40.6%) 
 > 70 376 (59.4%) 
CGI-Severity (n = 656)c  
Moderate (4) 199 (30.3%) 
Marked (5) 327 (49.9%) 
Severe or extreme (6 or 7) 130 (19.8%) 
ABC, Mean ± SD  
Irritability (n = 656) 22.7 ± 9.1 
Social Withdrawal (n = 656) 13.6 ± 8.6 
Stereotypic Behavior (n = 655) 7.6 ± 5.4 
Hyperactivity/Noncompliance (n = 655) 32.3 ± 9.0 
Inappropriate Speech (n = 654) 5.9 ± 3.5 
CASI ASD Total Scoree, Mean + SD (n = 654) 20.6 ± 7.3 
a RUPP (2002) did not collect maternal education 
b IQ not available in 25 subjects  
c CGI not available in 2 subjects 
d CGI-Improvement summarized only for patients receiving active study treatment 
e Summed score across 12 PDD items. Scores range 0 – 36.  
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Table 3. Rates of Diagnosis in Each Study  
 
 RUPP, 
2002 
(n = 101) 
RUPP, 
2005 
(n = 66) 
Aman et 
al., 2009 
(n = 124) 
Bearss et 
al., 2015 
(n =177) 
Scahill et 
al., 2015 
(n = 62) 
Handen et 
al., 2015 
(n = 128) 
Total 
(n = 658) 
ADHD 
72 
(71.2%) 
57 
(86.4%) 
105 
(84.7%) 
132 
(74.6%) 
59 
(95.2%) 
109 
(85.1%) 
534 
(81.1%) 
     ADHD combined 44 
(43.6%) 
40 
(60.6%) 
79 
(63.7%) 
72 
 (40.7%) 
34 
(54.8%) 
54 
(42.2%) 
323 
(49.1%) 
     ADHD hyperactive  11  
(10.9%) 
5  
(7.6%) 
7 
 (1.1%) 
38 
 (21.5%) 
8  
(12.9%) 
9  
(7.0%) 
78 
(11.9%) 
    ADHD inattentive  17  
(16.8%) 
12 
(18.2%) 
19 
(15.3%) 
22 
(12.4%) 
17 
(27.4%) 
46  
(35.9%) 
133 
(20.2%) 
ODD (n = 657) 42 
(41.6%) 
23 
(35.4%) 
78 
(62.9%) 
95 
 (53.7%) 
20 
(32.3%) 
41 
   (32.0%) 
299 
(45.5%) 
CD (n = 656) 19  
(19.0%) 
4    
(6.2%) 
27 
(21.8%) 
18 
 (10.2%) 
4    
 (6.5%) 
5 
(3.9%) 
77 
(11.7%) 
Any Anxiety Disorder (n = 657) 34 
 (33.7%) 
30 
(46.2%) 
54 
(43.6%) 
71 
 (40.1%) 
28 
(45.3%) 
58 
 (45.3%) 
275 
(41.9%) 
Generalized 18  
(17.8%) 
19 
(29.2%) 
30 
(24.2%) 
35 
 (19.8%) 
18 
(29.0%) 
40 
 (31.3%) 
160 
(24.4%) 
Social 22  
(21.8%) 
11 
(16.7%) 
31 
(25.0%) 
27 
 (15.3%) 
18 
(29.0%) 
32 
 (25.0%) 
141 
(21.4%) 
Separation 9 
 (8.9%) 
10 
(15.2%) 
21 
(16.9%) 
22 
 (12.4%) 
10 
(15.2%) 
7 
 (5.5%) 
74 
(11.3%) 
Any Mood Disorder 
7 
 (6.9%) 
4 
 (6.1%) 
13 
(10.5%) 
19 
 (10.7%) 
4  
(6.5%) 
2  
(1.6%) 
49  
(7.5%) 
Major Depression 
3  
(3.0%) 
1 
 (1.5%) 
4  
(3.2%) 
7 
 (4.0%) 
0  
(0%) 
1  
(0.8%) 
16  
(2.4%) 
Dysthymia 
7 
 (6.9%) 
4  
(6.1%) 
11 
 (8.9%) 
19 
 (10.7%) 
4 
 (6.5%) 
1  
(0.8%) 
46 
 (7.0%) 
Any Externalizing Disorder 
75  
(76.3%) 
58 
(89.2%) 
116 
(93.6%) 
148 
(83.6%) 
59 
(95.2%) 
112 
 (87.5%) 
568 
(86.5%) 
Any Internalizing Disorder 
36  
(35.6%) 
31 
(47.7%) 
57 
(46.0%) 
78 
 (44.1%) 
29 
(46.8%) 
59 
 (46.1%) 
290 
(44.1%) 
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Table 4a. Frequency of Concomitant Psychiatric Diagnoses in Children with and without ADHD1 
 
 
No ADHD 
(N = 123) 
ADHD 
(N = 534) 
Adjusted Odds 
Ratio (95% CI)2 
p-value 
ODD 33 (26.8%) 266 (49.8%) 2.7 (1.66 – 4.43) <0.001 
CD 6 (4.9%) 71 (13.3%) 3.0 (1.15 – 7.83) 0.025 
Anxiety Disorder 31 (25.2%) 244 (45.7%) 2.5 (1.37 – 4.55) 0.003 
Mood Disorder 7 (5.7%) 42 (7.9%) 1.4 (0.76 – 2.69) 0.272 
Internalizing  
Disorder 
33 (26.8%) 257 (48.1%) 2.5 (1.35 – 4.74) 0.004 
1Percents are percent of the column with the indicated diagnosis 2Adjusted for correlation of 
subjects nested within study.  
 
Table 4b. Frequency of Concomitant Psychiatric Diagnoses in Children with and without an 
Anxiety Disorder1 
 
 
No Anxiety 
Disorder 
(N = 382) 
Anxiety Disorder 
(N = 275) 
Adjusted Odds 
Ratio (95% CI)1 
p-value 
Any ADHD 290 (75.9%) 244 (88.7%) 2.5 (1.37 – 4.55) 0.003 
ODD 144 (37.7%) 155 (56.4%) 2.1 (1.39 – 3.28) <0.001 
CD 28 (7.4%) 49 (17.8%) 2.7 (2.13 – 3.51) <0.001 
Mood Disorder 15 (3.9%) 34 (12.4%) 3.5 (2.47 – 4.82) <0.001 
Externalizing Disorder 308 (80.6%) 260 (94.6%) 4.2 (1.86 – 9.34) <0.001 
1Percents are percent of the column with the indicated diagnosis 2Adjusted for correlation of 
subjects nested within study.  
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Table 5a.  Demographic Characteristics of Children with ASD by Concomitant Diagnostic Condition1, 2 
Co-occuring Disorder 
Group 
Sex Age IQ 
Male 
(N = 563) 
Female 
(N = 94) 
P-value 
≤6 year 
(N = 268) 
> 6 years 
(N = 390) 
p-value 
< 70 
(N = 257) 
≥ 70 
(N = 376) 
p-value 
ADHD 464 
 (82.3%) 
70  
(74.5%) 
0.073 
212  
(79.1%) 
322 
 (82.6%) 
0.265 
203 
 (79.0%) 
311  
(82.7%) 
0.239 
ODD 260  
(46.2%) 
39  
(41.5%) 
0.398 
139 
 (51.9%) 
160 
 (41.1%) 
0.007* 
96 
 (37.4%) 
195 
 (51.9%) 
<0.001* 
CD 64  
(11.4%) 
13  
(13.8%) 
0.496 
35 
 (13.1%) 
42 
 (10.8%) 
0.366 
35 
 (13.6%) 
40 
 (10.7%) 
0.260 
Any Anxiety Diosrder 237 
 (42.1%) 
38  
(40.4%) 
0.761 
103  
(38.4%) 
172  
(44.2%) 
0.140 
82 
 (31.9%) 
188 
 (50.0%) 
<0.001* 
Any Mood Disorder 42 
 (7.5%) 
7  
(7.5%) 
1.00 
23  
(8.6%) 
26  
(6.7%) 
0.358 
10 
 (3.9%) 
35 
 (9.3%) 
0.009* 
Internalizing  Disorder 249 
 (44.2%) 
41 
 (43.6%) 
0.912 
111 
 (41.4%) 
179 
 (46.0%) 
0.244 
85 
 (33.1%) 
197 
 (52.4%) 
<0.001* 
Externalizing  Disorder 492 
 (87.4%) 
76 
 (80.9%) 
0.086 
232 
 (86.6%) 
336  
(86.4%) 
0.944 
212 
 (82.5%) 
336 
 (89.4%) 
0.013* 
> 2 additional disorders * 373  
(66.1%) 
62 
 (66.0%) 
0.973 
180 
 (67.2%) 
255  
(65.4%) 
0.636 
148  
(57.6%) 
276 
 (73.4%) 
<0.001* 
1Groups are not mutually exclusive 2Percents are percent of the column with the indicated diagnosis 
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Table 5b. Clinical Characteristics of Children with ASD by Concomitant Condition1 
Co-occuring 
Disorder 
Group 
CGI-Severity 
ASD Score CGI-Improvement (N = 478) 
Moderate 
(N = 199) 
Marked 
(N = 327) 
Severe 
(N = 129) 
p-
value3 
≤ 20 
(N = 333) 
> 20 
(N = 321) 
p-value 
Non 
Response 
(N = 189) 
Positive 
Responder 
(N = 289) 
p-value 
ADHD 161 
(80.9%) 
262 
(80.1%) 
109 
(83.9%) 
0.573 
255 
(76.6%) 
277 
(86.3%) 
0.001* 
157  
(83.1%) 
232 
 (80.3%) 
0.443 
ODD 84 
(42.2%) 
144 
(44.0%) 
69 
(53.5%) 
0.060 
146 
(43.8%) 
153 
(47.7%) 
0.327 
71 
 (37.6%) 
148  
(51.2%) 
0.003* 
CD 20 
(10.1%) 
33 
(10.1%) 
24 
(18.6%) 
0.035* 
30 
(9.0%) 
47 
(14.7%) 
0.025* 
24 
 (12.8%) 
31 
 (10.7%) 
0.496 
Any Anxiety 
Disorder 
80 
 (40.2%) 
140 
 (42.8%) 
55 
(42.6%) 
0.619 
124 
(37.2%) 
150 
(46.7%) 
0.014* 
80 
 (42.3%) 
120 
 (41.5%) 
0.861 
Any Mood 
Disorder 
20 
 (10.1%) 
24 
 (7.3%) 
5 
(3.9%) 
0.037* 
19 
(5.7%) 
30 
(9.4%) 
0.077 
9 
 (4.8%) 
28 
 (9.7%) 
0.049 
Internalizing 
Disorder 
84 
 (42.4%) 
149  
(45.6%) 
57 
(44.2%) 
0.654 
132 
(39.6%) 
157 
(48.9%) 
0.017* 
85  
(45.0%) 
126  
(43.6%) 
0.767 
Externalizing 
Disorder 
173  
(86.9%) 
277  
(84.7%) 
116 
(89.9%) 
0.570 
276 
(82.9%) 
290 
(90.3%) 
0.005* 
165  
(87.3%) 
252 
(87.2%) 
0.973 
At least 2 
additional dx* 
127  
(63.8%) 
217  
(66.4%) 
89 
(68.5%) 
0.375 
206 
(61.9%) 
228 
(71.0%) 
0.013* 
126  
(66.7%) 
198 
 (68.5%) 
0.673 
1Groups are not mutually exclusive 2Percents are percent of the column with the indicated diagnosis 3Test for trend; Treating CGI as 
an ordinal outcome 
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Highlights 
 We observed a high frequency of multiple concomittant DSM-defined disorders  
 50% of children who met criteria for ADHD also met criteria for ODD 
 46% of children who met criteria for ADHD also met criteria for an anxiety disorder 
 Findings highlight the importance of improving diagostic practices in ASD 
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